Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other neoplasm 1

Conditions

Lung Neoplasms 2Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Whole-Body Irradiation 6Peripheral Blood Stem Cell Transplantation 6Biopsy 6fludarabine phosphate 5Immunohistochemistry 5Epoetin Alfa 5Cyclophosphamide 5Tacrolimus 4Methotrexate 4Gene Expression Profiling 4Celecoxib 4Mycophenolic Acid 3Microarray Analysis 3Imiquimod 3Etoposide 3Darbepoetin alfa 3Cyclosporine 3Colposcopy 3Busulfan 3Antilymphocyte Serum 3Aminolevulinic Acid 3Tomography, Optical Coherence 2Sirolimus 2Polymerase Chain Reaction 2Methylprednisolone 2Melphalan 2Mass Spectrometry 2Immunoenzyme Techniques 2Filgrastim 2Fatty Acids, Omega-3 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precancerous Conditions × Iloprost × Clear all
NCT00084409 2020-05-14

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

Phase 2 Completed
152 enrolled 18 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡